Study details
Enrolling now
Study of Novel Therapeutics for Acute Remedy of Colitis
Brigham and Women's Hospital
NCT IDNCT06420492ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
20
Study length
about 1.7 years
Ages
18–75
Locations
1 site in MA
About this study
Researchers are testing a treatment called BRS201 to see if it helps people with acute ulcerative colitis. The trial will last 609 days and involve taking the medication twice daily, tracking its use, and undergoing some tests. Participants will attend trial visits at a site.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take BRS201
PhasePhase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low14%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Body systems
Gastroenterology